All In Biotech

Drug Trial Radar · NCT07658339

A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39004 Inhalation Suspension in Patients With COPD

A Phase III Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Efficacy and Safety of HSK39004 Inhalation Suspension in the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Last checked: Nov 20, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 387 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

387

Planned (sponsor's estimate)

Start

Jul 11, 2026

Primary completion

Jun 11, 2027

Study completion Jun 11, 2027

Sponsor

Sponsor type
Industry
First posted
Jun 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of HSK39004 Inhalation Suspension in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).

Conditions

  • COPD (Chronic Obstructive Pulmonary Disease)

Interventions

  • HSK39004 Inhalation SuspensionDrug

    Dosage Formulation: HSK39004 Inhalation suspension Dosage 3mg,Twice Daily for 24 weeks

  • Placebo controlDrug

    Dosage Formulation: Placebo Inhalation suspension Dosage 0mg,Twice Daily for 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Average Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12h) at Week 12Time frame: Baseline (pre-dose on Day 1) and Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Third Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.